Akebia Therapeutics is recalling 17,664 bottles of Auryxia (ferric citrate) 210 mg tablets because the medication failed dissolution specifications. This prescription drug is sold in 200-count bottles and is used to control phosphorus levels in adults with chronic kidney disease on dialysis. The recall affects specific lots distributed nationwide with expiration dates in January and February 2022. Because the tablets may not dissolve properly, the medication may not be fully absorbed by the body, potentially reducing its effectiveness in managing the patient's condition.
When a drug fails dissolution specifications, it may not break down as intended in the digestive tract, preventing the active ingredient from being properly absorbed into the bloodstream. This can lead to a lack of efficacy, meaning the patient's phosphorus levels may not be adequately controlled, which is a critical part of managing chronic kidney disease.
Drug recall remedy for failed dissolution
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.